Schedule III Ends 280E Tax Penalty: What It Means for Cannabis Businesses

The Tax Change Cannabis Businesses Have Waited a Decade For

For years, cannabis businesses have operated under one of the most punishing tax provisions in the American tax code. Section 280E of the Internal Revenue Code prevented any business trafficking in Schedule I or II controlled substances from deducting ordinary business expenses — rent, payroll, marketing, utilities — from their federal tax returns. The result was effective tax rates that sometimes exceeded 70 percent, crippling profitability and driving many operators out of business.

That era officially ended in April 2026 when the Department of Justice moved state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act. Because Section 280E applies only to Schedule I and II substances, this reclassification immediately freed qualifying cannabis businesses from the punitive tax treatment that had defined the industry's financial landscape since its inception.

Consumers should expect a slow drip of pricing and selection improvements as 280E savings work through the supply chain. To watch how it lands locally, find a dispensary near you on Budpedia and compare menu prices against what you saw three months ago.

Understanding Section 280E

Section 280E was enacted in 1982 after a drug dealer successfully argued in tax court that he should be able to deduct business expenses from his illegal drug sales. Congress responded by creating a provision specifically preventing businesses involved in trafficking Schedule I or II controlled substances from taking standard business deductions.

When states began legalizing cannabis, this provision created an absurd situation: businesses operating legally under state law, paying state taxes, employing workers, and serving customers were simultaneously denied the basic tax deductions available to every other legal business. A cannabis dispensary could not deduct its rent, employee wages, or marketing costs, while the liquor store next door deducted all of these without issue.

The financial impact was devastating. Cannabis businesses routinely faced effective federal tax rates between 50 and 80 percent, far exceeding what any other industry pays. Many operators survived only by structuring complex cost-of-goods-sold calculations — the one deduction 280E did allow — to capture as many expenses as possible under that narrow category.

What Actually Changed with Schedule III

The DOJ's April 2026 order moved two categories of marijuana to Schedule III: FDA-approved marijuana products and marijuana products regulated by state medical marijuana licenses. This means state-licensed medical cannabis operators can now deduct ordinary business expenses just like any other business.

However, the change is not universal. All recreational marijuana — including products sold in adult-use dispensaries — remains Schedule I under this order. This creates a bifurcated system where medical operators benefit from normal tax treatment while recreational businesses continue to suffer under 280E.

For businesses operating in states with both medical and recreational programs, this creates complex accounting challenges. Operators with dual licenses must carefully separate medical and recreational revenue streams and allocate expenses accordingly. The IRS has not yet issued detailed guidance on how this allocation should work in practice.

Financial Impact on the Industry

Industry analysts estimate that the elimination of 280E for medical cannabis could save qualifying businesses between 40 and 60 percent on their effective tax rates. For a mid-sized dispensary doing $5 million in annual revenue, this could translate to hundreds of thousands of dollars in annual tax savings.

The broader industry impact extends beyond individual business finances. Lower tax burdens mean more capital available for expansion, hiring, product development, and compliance improvements. Businesses that were barely surviving under 280E may now have room to invest in growth, while operators that avoided entering the cannabis space due to the punitive tax treatment may reconsider.

The cannabis industry contributed approximately $123 billion to the U.S. economy in 2025, with projections of $135 billion for 2026. Retail sales alone are expected to exceed $50 billion in 2026. The removal of 280E for a significant portion of these businesses could accelerate growth substantially.

The IPO and Investment Implications

The end of 280E for medical cannabis has already sparked renewed investor interest in the sector. Cannabis pharma companies are exploring initial public offerings, and ETF investors are returning to cannabis-focused funds. The ability to demonstrate normal profitability — rather than profitability despite a crippling tax burden — makes cannabis businesses far more attractive to institutional investors who previously avoided the sector.

For publicly traded multi-state operators (MSOs), the impact on financial statements will be immediate and dramatic. Quarterly earnings reports following the rescheduling should show substantial improvements in net income, even without any change in underlying business performance. This "paper" improvement in profitability could drive significant stock price appreciation.

Private equity and venture capital firms that have been cautiously circling the cannabis industry may also increase their involvement. The combination of normal tax treatment, federal banking access improvements, and a more stable regulatory environment creates conditions that institutional capital typically requires before making significant commitments.

Complications and Concerns

The situation is not without complications. The DEA has announced an expedited administrative hearing beginning June 29, 2026, to consider broader rescheduling of all marijuana from Schedule I to Schedule III. Until that process concludes, recreational cannabis businesses remain subject to 280E.

Additionally, the current order creates a competitive imbalance between medical and recreational operators. In states where both programs exist, medical dispensaries suddenly have a significant cost advantage over their recreational counterparts. This could distort market dynamics and potentially incentivize creative regulatory arbitrage.

There are also questions about retroactive application. Some cannabis businesses have filed amended tax returns seeking refunds for previously disallowed deductions, arguing that the rescheduling should apply retroactively. The IRS has not yet clarified whether it will accept such claims, and the legal theory supporting retroactivity is untested.

What Businesses Should Do Now

Cannabis businesses with state medical licenses should immediately review their tax positions and consider consulting with tax professionals experienced in cannabis accounting. Key steps include reviewing expense categorization to ensure all legitimate deductions are being claimed, evaluating whether amended returns for prior years may be appropriate, and restructuring operations to maximize the benefit of normal tax treatment.

Businesses should also document their licensing status carefully, as the 280E exemption applies specifically to operations conducted under qualifying state medical marijuana licenses. Clear documentation of which revenue and expenses relate to medical versus recreational operations will be essential for tax compliance.

The Path to Full Relief

The June 2026 hearing on broader rescheduling could eventually extend 280E relief to all cannabis businesses, not just medical operators. If the DEA concludes that all marijuana should be classified as Schedule III, recreational operators would gain the same tax benefits currently limited to medical license holders.

However, that process is expected to take months and potentially face legal challenges. In the meantime, the cannabis industry exists in a transitional state where the tax landscape depends heavily on a business's specific licensing category and the regulatory framework of its home state.

For an industry that has operated under extraordinary financial constraints since its inception, the end of 280E for medical cannabis represents a watershed moment. It validates the economic viability of legal cannabis businesses and removes one of the most significant barriers to the industry's maturation into a normalized sector of the American economy.